EGFL7 and systemic sclerosis: After EGFL7 silencing in SSc-FBs treated with TGF-β, we observed an increase in COL1A1 production compared to untreated SSc-FBs, suggesting that the modulation of COL1A1 expression in SSc is TGF-β dependent.